viagenpumatucel-L (HS-110)

News alerts, weekly reports and conference planners

Company:

Scorpius Holdings

Drug class:

Endoplasmin modulator, Endoplasmin stimulant

‹

›

almost3years

[VIRTUAL] TetTCRII-SeqHD: High-dimensional analysis of antigen-specific ex vivo CD4+ T cells (IMMUNOLOGY 2021)

We also found explicit differences in the phenotypes of antigen specific cells within the tumor and a paired healthy tissue sample. Conclusions In conclusion, we validate the use of a high-throughput technology for assessing the specificity, phenotype, TCR, and gene expression patterns in antigen-specific CD4+ T cells in peripheral blood and tumor infiltrating lymphocytes.

almost 3 years ago

Preclinical

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)

viagenpumatucel-L (HS-110) • gp96-Ig vaccine

almost4years

[VIRTUAL] Impact of adding viagenpumatucel-L to nivolumab in non-small cell lung cancer (NSCLC) patients with low levels of tumour infiltrating lymphocytes (ESMO 2020)

Legal entity responsible for the study: Heat Biologics, Inc. Funding: Heat Biologics, Inc.

almost 4 years ago

Clinical • Tumor-Infiltrating Lymphocyte

CD8 (cluster of differentiation 8)

TILs

Opdivo (nivolumab) • viagenpumatucel-L (HS-110)

4years

[VIRTUAL] Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab. (ASCO 2020)

The combination of HS-110 and nivolumab appears safe and well tolerated. OS was improved in pts whose tumors express ≥ 8 shared antigens with HS110, as well as in those who specifically expressed ZNF492. Further exploration of antigen expression as a predictor for treatment outcome with HS110 plus nivolumab is ongoing.

4 years ago

Clinical • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8)

Opdivo (nivolumab) • viagenpumatucel-L (HS-110)